- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Amgen contends with data breach, exposing patient information | ||
| 17:46 | AstraZeneca shares slump after $400bn BMS merger rumours | ||
| 11:46 | IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib | ||
| 10:46 | Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy | ||
| Fr | Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns | ||
| Fr | J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout | ||
| Fr | miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies | ||
| Fr | Resilience and Lilly to increase US medicines production with $750m investment | ||
| Do | Pfizer seeks label expansion for Litfulo after double Phase III NSV win | ||
| Do | EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals | ||
| Do | FDA AdCom shuns Capricor's DMD cell therapy amid data dispute | ||
| Do | The $1.2tn untapped pharma opportunity in tropical conservation | ||
| Do | Amgen's Repatha receives positive CHMP opinion for broader cardiovascular use | ||
| Do | Synlogic and Caldera sign merger agreement | ||
| Mi | AdCom expected for uniQure's Huntington's gene therapy, chief medical officer says | ||
| Mi | GSK eyes future growth with cost-cutting plan amid promising Q2 | ||
| Mi | FDA grants fast track designation for HAYA Therapeutics' HTX-001 | ||
| Mi | Eisai and CORE Biomedicine agree on global licence for oncology pipeline | ||
| Di | Leadership changes afoot at two CGT biotechs | ||
| Di | Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development | ||
| Di | BioMarin and n-Lorem partner on early research for ReNU syndrome therapy | ||
| Di | argenx signs agreement to buy Forte Biosciences for $2.2bn | ||
| 27.07. | Outlook Therapeutics wins FDA approval for Lytenava in wet AMD | ||
| 27.07. | Biointron introduces RushData platform for AI-driven antibody discovery | ||
| 27.07. | Kenvue's Tylenol with Naproxen gains FDA approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.